Carcinoid syndrome natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 19: | Line 19: | ||
:*The size of the primary tumor | :*The size of the primary tumor | ||
:*The anatomical extent of disease | :*The anatomical extent of disease | ||
*Elevated expression of the proliferation antigen Ki-67 and the tumor suppressor protein p53 have been associated with poorer prognosis | *Elevated expression of the proliferation antigen Ki-67 and the tumor suppressor protein p53 have been associated with poorer prognosis. | ||
*Adverse clinical prognostic indicators include: | *Adverse clinical prognostic indicators include: | ||
:*Carcinoid syndrome | :*Carcinoid syndrome | ||
:*Carcinoid heart disease | :*Carcinoid heart disease | ||
:*High concentrations of the tumor markers urinary [[5-HIAA]] and plasma [[chromogranin A]] | :*High concentrations of the tumor markers urinary [[5-HIAA]] and plasma [[chromogranin A]]. | ||
*In people with the carcinoid syndrome, the tumor has usually spread to the liver, which lowers the survival rate | *In people with the carcinoid syndrome, the tumor has usually spread to the liver, which lowers the survival rate | ||
*The outlook is more favorable with new treatment methods, such as [[sandostatin]] | *The outlook is more favorable with new treatment methods, such as [[sandostatin]].. | ||
==References== | ==References== |
Revision as of 18:35, 22 September 2015
Carcinoid syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Carcinoid syndrome natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Carcinoid syndrome natural history, complications and prognosis |
FDA on Carcinoid syndrome natural history, complications and prognosis |
CDC on Carcinoid syndrome natural history, complications and prognosis |
Carcinoid syndrome natural history, complications and prognosis in the news |
Blogs on Carcinoid syndrome natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Complications
- Increased risk of falls and injury (from hypotension)
- Bowel obstruction (from tumor)
- Gastrointestinal bleeding
- Right-sided heart failure
- Serotonin causes fibrosis of the tricuspid valve and pulmonary valve, more rarely the mitral valve in cases with left sided involvement
- "TIPS" - Tricuspid Insufficiency, Pulmonic Stenosis (fibrosis of tricuspid and pulmonary valves)
Prognosis
- Factors that determine the clinical course and outcome of patients with GI carcinoid tumors are complex and multifaceted and include the following:[1]
- The site of origin
- The size of the primary tumor
- The anatomical extent of disease
- Elevated expression of the proliferation antigen Ki-67 and the tumor suppressor protein p53 have been associated with poorer prognosis.
- Adverse clinical prognostic indicators include:
- Carcinoid syndrome
- Carcinoid heart disease
- High concentrations of the tumor markers urinary 5-HIAA and plasma chromogranin A.
- In people with the carcinoid syndrome, the tumor has usually spread to the liver, which lowers the survival rate
- The outlook is more favorable with new treatment methods, such as sandostatin..
References